Veeva Systems (VEEV) to Release Quarterly Earnings on Wednesday

Key Points

• Veeva Systems is set to announce its Q2 2026 earnings on August 27th, with analysts predicting earnings of $1.90 per share and revenue of approximately $768 million.
• In its latest quarterly report, Veeva reported earnings of $1.97 per share, exceeding analysts' expectations and achieving a revenue growth of 16.7% year-over-year.
• Insider transactions showed that key executives sold shares recently, indicating a potential shift in sentiment among company leadership as insiders sold over 1,378 shares in the last three months.

Veeva Systems (NYSE:VEEV - Get Free Report) is expected to post its Q2 2026 results after the market closes on Wednesday, August 27th. Analysts expect Veeva Systems to post earnings of $1.90 per share and revenue of $768.4940 million for the quarter. Individuals can find conference call details on the company's upcoming Q2 2026 earningreport page for the latest details on the call scheduled for Wednesday, August 27, 2025 at 5:00 PM ET.

Veeva Systems (NYSE:VEEV - Get Free Report) last released its earnings results on Wednesday, May 28th. The technology company reported $1.97 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.23. The business had revenue of $759.04 million for the quarter, compared to the consensus estimate of $728.38 million. Veeva Systems had a return on equity of 13.96% and a net margin of 27.34%.The business's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.50 earnings per share. On average, analysts expect Veeva Systems to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Veeva Systems Stock Up 3.1%

Shares of NYSE VEEV traded up $8.75 during midday trading on Friday, hitting $291.03. The stock had a trading volume of 961,444 shares, compared to its average volume of 1,080,466. The company has a market capitalization of $47.56 billion, a PE ratio of 61.66, a P/E/G ratio of 2.30 and a beta of 0.95. The stock has a 50 day simple moving average of $282.35 and a 200-day simple moving average of $252.59. Veeva Systems has a 1 year low of $196.10 and a 1 year high of $296.72.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Mizuho raised their target price on Veeva Systems from $280.00 to $295.00 and gave the company an "outperform" rating in a research report on Monday, June 2nd. Wells Fargo & Company raised their target price on Veeva Systems from $285.00 to $300.00 and gave the company an "overweight" rating in a research report on Thursday, May 29th. Truist Financial raised their target price on Veeva Systems from $217.00 to $230.00 and gave the company a "hold" rating in a research report on Thursday, May 29th. Morgan Stanley increased their price target on Veeva Systems from $201.00 to $210.00 and gave the company an "underweight" rating in a report on Thursday, May 29th. Finally, Wall Street Zen raised Veeva Systems from a "hold" rating to a "buy" rating in a report on Friday, May 30th. Fourteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $274.17.

Insider Activity

In other news, SVP Jonathan Faddis sold 720 shares of Veeva Systems stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $285.62, for a total value of $205,646.40. Following the completion of the sale, the senior vice president directly owned 7,902 shares of the company's stock, valued at approximately $2,256,969.24. The trade was a 8.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Priscilla Hung sold 171 shares of Veeva Systems stock in a transaction on Monday, July 7th. The shares were sold at an average price of $284.40, for a total value of $48,632.40. Following the completion of the sale, the director directly owned 3,966 shares of the company's stock, valued at $1,127,930.40. The trade was a 4.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,378 shares of company stock valued at $394,217. 10.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rakuten Securities Inc. boosted its holdings in Veeva Systems by 56.7% in the second quarter. Rakuten Securities Inc. now owns 163 shares of the technology company's stock valued at $47,000 after purchasing an additional 59 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Veeva Systems by 58.7% in the second quarter. Tower Research Capital LLC TRC now owns 668 shares of the technology company's stock valued at $192,000 after purchasing an additional 247 shares during the period. IHT Wealth Management LLC purchased a new position in Veeva Systems in the second quarter valued at $201,000. Curi Capital LLC purchased a new position in Veeva Systems in the second quarter valued at $312,000. Finally, Oxford Asset Management LLP purchased a new position in Veeva Systems in the second quarter valued at $321,000. 88.20% of the stock is currently owned by hedge funds and other institutional investors.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.